Press Releases
Prior announcements are available on the ASX website.
December 19, 2019
ResApp to Undertake a Clinical Study of COPD Screening in Indigenous Australians
November 29, 2019
ResApp and Coviu to Deploy ResAppDx-EU on Coviu’s Telehealth Platform
November 15, 2019
ResApp Grants Option to Consumer Health Business Unit of Sanofi for Consumer Product
October 4, 2019
ResApp Selected to Join the Startup Creasphere Digital Health Program
October 2, 2019
ResApp Receives Australian TGA Approval for Smartphone-based Diagnostic Test for Paediatric Respiratory Disease
September 30, 2019
ResApp Receives Positive Results from Prospective At-Home Sleep Apnoea Study
September 26, 2019
ResApp Receives CE Mark Approval for Smartphone-based Diagnostic Test for Adult and Paediatric Respiratory Disease
August 23, 2019
ResApp Receives CE Mark for the World’s First Smartphone-based Diagnostic Test for Respiratory Disease
July 1, 2019
At-Home Obstructive Sleep Apnoea Study Update
June 12, 2019
ResApp Receives $1.785 Million R&D Tax Incentive Cash Rebate
June 6, 2019
Breathe Easy Paediatric Study Published in Peer-Reviewed Journal
June 5, 2019
ResApp Appoints Renowned Healthcare Leaders to Industry Advisory Board
May 29, 2019
Customised Hardware and Wearable Devices to Expand ResApp’s Addressable Markets
April 15, 2019
ResApp Submits De Novo Application to the FDA for Smartphone-based Diagnosis of Paediatric Respiratory Disease
March 29, 2019
ResApp Provides Update on Australian Adult Study and FDA De Novo Submission
March 18, 2019
ResApp Provides Updated Top-line Results from SMARTCOUGH-C-2 Study
March 13, 2019
ResApp Receives R&D Advanced Overseas Finding
January 2, 2019
ResApp Submits CE Mark Technical File for Acute Respiratory Disease Diagnostic Smartphone Application
November 14, 2018
ResApp Clears Major Milestone for CE Mark and TGA Approval with ISO 13485 Compliance
November 5, 2018
ResApp Receives Notice of Allowance for Core Patent in Japan
October 20, 2018
ResApp Reports Positive Preliminary Results from SMARTCOUGH-C-2 Study for Diagnosis of Childhood Respiratory Disease using Cough Sounds
October 11, 2018
ResApp Announces Positive Results from Prospective Sleep Apnoea Clinical Study
October 2, 2018
ResApp Completes Recruitment in Prospective Sleep Apnoea Study
September 27, 2018
ResApp Provides Update on SMARTCOUGH-C-2 Study Timing
September 19, 2018
ResApp Successfully Completes $7.5 Million Capital Raising
September 3, 2018
ResApp Announces Positive Top-line Results from Australian Prospective Paediatric Clinical Study
August 16, 2018
ResApp Partners with Lockheed Martin for U.S. Government Agency Research Program
August 15, 2018
ResApp Receives Notice of Acceptance for Core Patent in Australia
August 2, 2018
ResApp Completes Enrolment in Australian Paediatric Clinical Study
August 1, 2018
ResApp Completes Enrolment in SMARTCOUGH-C-2 Study
July 12, 2018
ResApp Provides Obstructive Sleep Apnoea Study Update
June 28, 2018
ResApp Provides Update on Australian Clinical Study
June 6, 2018
ResApp Receives Notice of Allowance for Core Patent in US
May 31, 2018
ResApp Provides SMARTCOUGH-C-2 Study Update
April 26, 2018
ResApp Receives R&D Tax Incentive Cash Rebate for FY17
April 24, 2018
ResApp Signs LOI with German Private Hospital Network for Pilot Project
April 10, 2018
ResApp Announces Development of Obstructive Sleep Apnoea Screening Test
March 9, 2018
ResApp Provides SMARTCOUGH-C-2 Study Update
January 11, 2018
ResApp Receives Third Institutional Review Board Approval for SMARTCOUGH-C-2 Study
January 8, 2018
ResApp Enrols First Patient in SMARTCOUGH-C-2 Study
December 29, 2017
ResApp Appoints Non-Executive Director
December 19, 2017
ResApp Receives Institutional Review Board Approval at Massachusetts General Hospital for SMARTCOUGH-C-2 Study
December 18, 2017
ResApp Announces Further Positive Results from Australian Adult Clinical Studies
December 13, 2017
ResApp Receives Institutional Review Board Approval at Texas Children’s Hospital for SMARTCOUGH-C-2 Study
September 14, 2017
Update on Field Evaluation by Médecins Sans Frontières/Doctors Without Borders
September 4, 2017
SMARTCOUGH-C Study and Paediatric Clinical Strategy Update
August 23, 2017
Dr Philip Currie Joins ResApp’s Scientific Advisory Board
August 21, 2017
ResApp Receives R&D Tax Incentive Cash Refund for FY16
August 9, 2017
ResApp Reports Preliminary Top-line Results from SMARTCOUGH-C Study for Diagnosis of Childhood Respiratory Disease using Cough Sounds
June 22, 2017
ResApp Provides Updated Australian Paediatric Study Results
June 19, 2017
ResApp Announces Completion of Enrolment in SMARTCOUGH-C Study
May 30, 2017
ResApp Provides SMARTCOUGH-C May Study Update
April 28, 2017
ResApp Licenses Additional Pneumonia Diagnostic Tool from UniQuest
April 19, 2017
ResApp Extends SMARTCOUGH-C Study
March 21, 2017
ResApp to Present at Upcoming Conferences in March
March 15, 2017
ResApp Provides SMARTCOUGH-C Study Update
January 10, 2017
ResApp Announces Expanded Research Collaboration with Massachusetts General Hospital
December 9, 2016
ResApp Initiates SMARTCOUGH-C Study Evaluating Efficacy of ResAppDx for Diagnosing Childhood Respiratory Disease
November 28, 2016
ResApp to Present at Wilsons Healthcare IT Conference
November 16, 2016
ResApp Receives Institutional Review Board Approval at Texas Children’s Hospital for SMARTCOUGH-C Study
November 11, 2016
ResApp Receives Institutional Review Board Approval at Massachusetts General Hospital for SMARTCOUGH-C Study
October 25, 2016
ResApp Receives Australian Emerging Company of the Year Award at the “Johnson & Johnson Innovation Industry Excellence Awards”
October 21, 2016
ResApp Receives First Institutional Review Board Approval for SMARTCOUGH-C Study
October 12, 2016
ResApp Wins Innovation Excellence Award at Tech23 2016
October 3, 2016
ResApp Announces Further Positive Results from Adult Clinical Study
September 15, 2016
ResApp Begins Field Evaluation with Leading Global Humanitarian Organisation
August 19, 2016
ResApp Wins Global Grand Finals at the 2016 Talent Unleashed Awards
August 18, 2016
ResApp Expands Diagnostic Application to the Management of Respiratory Disease
July 22, 2016
ResApp Wins Category at the 2016 Talent Unleashed Awards
July 20, 2016
ResApp Announces Massachusetts General Hospital as First US Clinical Study Site
June 30, 2016
ResApp Provides Update on US Clinical Study
June 21, 2016
ResApp Announces Positive Preliminary Results from Adult Clinical Study
June 7, 2016
ResApp Provides Australian Adult Study Enrolment Update
April 20, 2016
ResApp Completes Oversubscribed $12.5 Million Capital Raising to Expand Market Opportunity
March 31, 2016
ResApp Provides Updated Paediatric Clinical Study Results
March 14, 2016
ResApp Completes Successful Pre-Submission Meeting with the US FDA
March 2, 2016
ResApp Achieves Breakthrough Performance in Paediatric Clinical Study
February 26, 2016
Second Site Added to Adult Clinical Study
January 22, 2016
ResApp to Exhibit at the McKinsey Future of Digital Healthcare Conference in Dubai
December 31, 2015
ResApp Files Pre-Submission Package with the US FDA
December 14, 2015
ResApp Receives Approval to Begin Adult Study
November 10, 2015
Further Positive Preliminary Results from Clinical Study
November 4, 2015
ResApp to Exhibit at the McKinsey Global Integrated Care Conference in Sydney
October 22, 2015
ResApp’s Dr Abeyratne to present at the inaugural Pneumonia Innovations Summit in New York
September 30, 2015
Positive preliminary results from current clinical study for diagnosing respiratory disease
September 3, 2015
FDA Consultant Engagement
September 1, 2015
Clinical Study Update
August 12, 2015
Second Site Added To Clinical Study
July 31, 2015
Quarterly Commentary – Q2 2015
July 17, 2015
ResApp Appoints New Chairman, Dr Roger Aston
July 14, 2015
ResApp Shares Commence Trading on the ASX and Patient Enrolment Complete for Clinical Study
MEDIA INQUIRIES
Brian Leedman
VP, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
CONTACT US
+61 7 3724 0035
General Information
Clinical Studies
Investor Relations
LEGAL
Terms of Use
Privacy Policy
ResAppDx-US is pending review of a request for De Novo classification and is not available for sale in the United States.
© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.